Novartis· @Novartis · X·· 21 天前AI 评分42
AI 导读
诺华第三季度实现稳健的销售增长和核心利润率扩张,优先品牌和上市新品足以抵消仿制药侵蚀。 我们已上调2026年全年核心营业收入指引*。 新闻稿链接:https://novartis.social/6018aLrvy #NVSQ326
正文
Novartis delivered solid sales growth and core margin expansion in Q3, as priority brands and launches more than offset generic erosion.
We have raised our full-year 2026 guidance* for core operating income.
Link to press release: https://novartis.social/6018aLrvy
#NVSQ326
来源:Novartis · x.com